Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy / 中国肺癌杂志
Chinese Journal of Lung Cancer
; (12): 477-481, 2022.
Article
em Zh
| WPRIM
| ID: wpr-939734
Biblioteca responsável:
WPRO
ABSTRACT
Proteolysis targeting chimeria (PROTAC) degrades target proteins by utilizing the ubiquitin-proteasome pathway, subverting the concept of traditional small molecule inhibitors. Among the common mutation targets of non-small cell lung cancer (NSCLC), PROTAC technology has successfully achieved the effective degradation of kirsten rat sarcoma viral oncogene homolog (KRAS), epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK ) and other proteins in preclinical studies. PROTAC drugs with their unique event-driven advantages, are expected to overcome acquired drug resistance caused by small molecule inhibitors and show good therapeutic potential for undruggable targets, thereby providing a new strategy for the treatment of NSCLC.
.
Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Proteínas Proto-Oncogênicas p21(ras)
/
Carcinoma Pulmonar de Células não Pequenas
/
Inibidores de Proteínas Quinases
/
Proteólise
/
Neoplasias Pulmonares
/
Mutação
Limite:
Humans
Idioma:
Zh
Ano de publicação:
2022
Tipo de documento:
Article